Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.
Project Integrum is a large-scale R&D project designed to discover novel therapeutic antibodies for more than 1000 druggable targets. The project, which was initiated in March 2020, includes the following core milestones:
- Knock-out of 1000 pre-selected drug targets in RenMab TM and/or RenLite ® fully human antibody mice
- Leveraging these target KO RenMice (RenMice HiTS Platform) and high-throughput screening capabilities to establish an off-the-shelf library of fully human antibody hits exhibiting species cross-reactivity, as well as broader sequence and epitope diversity
- Streamlined identification of preclinical candidates (PCC) using Biocytogen’s innovative mouse models and in vivo/in vitro pharmacology platforms
- Development of antibody candidates into various drug modalities through joint or internal research, including monoclonal antibodies, bispecific antibodies, and ADCs.
The company has officially completed the first two milestones on schedule; nearly 1000 target KO RenMice® strains have been generated, more than 900 target antibody discovery projects have been completed, and a library containing 400-500K fully human antibody sequences has been established. 30+ PCC-stage molecules have also been successfully identified.
The rapid progress of the project has directly led to the exponential growth of Biocytogen’s antibody licensing and co-development business, with 50 antibody asset-based co-development/out-licensing/transfer agreements established, including partnerships with 6 multinational pharmaceutical companies. In addition, 5 collaborative products are expected to submit IND applications and start clinical trials in 2024. As the number of co-development products entering clinical trials increases, Biocytogen's ongoing business growth will be fueled not only by upfront payments but also by milestone payments.
As Project Integrum shifts focus to the latter milestones, the company will work with collaborators to expedite the development of selected antibodies against key targets to enter into the clinic.
Dr. Yuelei Shen, President and CEO of Biocytogen, said: “Project Integrum aims to overcome several difficulties in the field, such as crowded target selection and high cost, time-consuming antibody discovery. Species cross-reactive fully human antibodies derived from our platform can significantly reduce preclinical research time and cost, while improving the rate of translational success. We adopt an open, flexible and diverse business model to share our antibody repertoire and resources with global partners to reduce their development costs and increase the success rate by minimizing redundant investments and improving resource utilization efficiency. We welcome more collaborators to join us in this endeavor, working together to develop better antibody drugs that will benefit patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice® HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817088666/en/
Contact information
Biocytogen
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International and HSBC Test New Cross-Border Payments Solution Using Tokenised Deposits on Swift’s Network and Powered by ISO 2002211.12.2025 05:00:00 EET | Press release
Ant International, HSBC and Swift today have completed a successful Proof of Concept (POC) for the cross-border transfer of tokenised deposits using ISO 20022 standards. The initiative leverages Swift’s global messaging network and HSBC’s recently launched Tokenised Deposit Service, combined with Ant International’s blockchain technology. The POC marks a key milestone in Ant International, HSBC, and Swift’s efforts to help businesses unlock the full benefits of tokenisation for enhanced liquidity, programmable finance, and 24/7 real-time settlement. As part of this initiative, Ant International and HSBC successfully integrated Ant International’s in-house blockchain infrastructure with Swift’s networks, enabling real-time treasury management across borders through HSBC Singapore and Hong Kong, via HSBC’s Tokenised Deposit Service. With the introduction of a common protocol co-built with Swift and HSBC, this could remove the need for Ant International to establish individual bilateral a
Canva Unveils 2026 Design Trends: The Year of ‘Imperfect by Design’11.12.2025 00:52:00 EET | Press release
Canva, the world’s leading all-in-one visual communication platform, today unveiled its third annual Design Trends Report with bold predictions for creativity, social media and brand content in 2026. The company also unveiled a “Design DNA” feature, which offers Canva users a custom recap that celebrates their creative output in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210696597/en/ Canva Design DNA Trends from Creators, for Creators By analyzing design and search activity, expert insights from the Canva Designer Advisory Board, and a survey of 1,000 creators across the U.S. and Brazil, Canva has identified 10 design trends that will shape creative and design culture in 2026. The findings paint a clear picture: as creators embrace AI’s power, they also crave the human touches that make design feel personal. A New Creative Standard: Imperfect by Design As AI technology raises the baseline for what's possible, v
Audiencerate Achieves Google Customer Match Partner Status, strengthening its role as a Global Data Provider10.12.2025 23:40:00 EET | Press release
Audiencerate, an international technology company specializing in data activation solutions and platforms within the AdTech and MarTech sectors, has been officially awarded by Google as a Customer Match Upload Partner. This certification is granted to a restricted number of global operators (https://support.google.com/google-ads/answer/7361372?hl=en) authorized to manage and onboard first-party data into the Google Ads and DV360 ecosystem. The company strengthen its strategic partnership with Google by adding the Customer Match Upload Partner accreditation to its existing status as a certified Google Data Provider. This new credential enables Audiencerate to seamlessly integrate proprietary audience segments and data into Google’s advertising platforms. The combination of these two accreditations represents an exceptionalsituation in the international landscape and solidifies Audiencerate's position in the digital advertising market, which is increasingly reliant on first-party data. T
Defence, Security and Resilience Bank (DSRB) Development Group – Official Statement10.12.2025 22:06:00 EET | Press release
On 8 September 2025, the Defence, Security and Resilience Bank (DSRB) Development Group convened a high-level meeting in the City of London with representatives from 37 nations, including all G7 members, alongside the European Commission, NATO, European Parliament, Global Banks, and Ratings Agencies to discuss the DSRB. A number of countries have now indicated their intention to begin the formal steps required to bring the DSRB into existence. This phased pattern of engagement is standard in the creation of international financial institutions, which typically begin with a core group of anchor nations and expand as additional members join through charter negotiations and subsequent capital rounds. The DSRB is designed to complement the European Union’s SAFE initiative, offering a broader multilateral platform that brings together NATO and Indo-Pacific nations and mobilises global capital to build the balance-sheet capacity required to finance nations’ defence spending and long-term res
ClickUp 4.0's Craft & Quality is Available Today, Maximizing Human Productivity10.12.2025 20:26:00 EET | Press release
ClickUp today announced the launch of ClickUp 4.0, a groundbreaking release designed to end the chaos of work sprawl and usher in a new era of work. With a bold vision for the convergence of software, people, and AI, ClickUp 4.0 delivers a suite of powerful new features that empower teams to do their best work in one converged workspace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210712132/en/ A new era of ClickUp For years, organizations have struggled with fragmented workflows, siloed tools, and the constant friction of context switching. ClickUp 4.0 is the answer: a single, beautifully crafted workspace that brings together tasks, docs, goals, chat, and AI-powered automation. The result is a platform that not only saves time but also sparks creativity and collaboration at every level. “Software is converging - we always knew it would. And it's about time, because work sprawl is the silent killer of productivity," s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom